Literature DB >> 10051767

mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons.

M Lafon-Cazal1, L Fagni, M J Guiraud, S Mary, M Lerner-Natoli, J P Pin, R Shigemoto, J Bockaert.   

Abstract

Glutamate-induced glutamate release may be involved in the delayed neuronal death induced by N-methyl-D-aspartate (NMDA). In order to examine a possible modulatory effect of the presynaptic group III mGluRs on glutamate excitotoxicity, the effect of L-2-amino-4-phosphonobutyrate (L-AP4) was examined on NMDA-induced delayed death of mouse cerebellar granule neurons in culture. We found that L-AP4, at high concentration (in the millimolar range), inhibited in a non-competitive manner the NMDA-induced toxicity. This effect was mimicked by high concentration of L-serine-o-phosphate (L-SOP), and was inhibited by pertussis toxin (PTX) indicating the involvement of a Gi/o protein. This suggests the involvement of mGluR7 in the L-AP4 effect, and this was consistent with the detection of both mGluR7 protein and mRNA in these cultured neurons. To examine the mechanism of the L-AP4-induced protection from excitotoxic damage, the effect of L-AP4 on glutamate release was examined. L-AP4 (> or = 1 mM) noncompetitively inhibited by more than 60% the glutamate release induced by NMDA during the insult. We also observed that the 10-min NMDA receptor stimulation resulted in a dramatic increase in the extracellular glutamate concentration reaching 6000% of the control value 24 h after the insult. This large increase was also inhibited when NMDA was applied in the presence of > or = 1 mM L-AP4. Part of the L-AP4-induced protection from excitotoxic damage of granule neurons may therefore result from the inhibition of the vicious cycle: dying cells release glutamate, glutamate induced cell death. The present results add to the hypothesis that presynaptic mGluRs, probably mGluR7, may be the targets of drugs decreasing glutamate release and then neuronal death observed in some pathological situations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051767     DOI: 10.1046/j.1460-9568.1999.00475.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  17 in total

1.  PICK1 is required for the control of synaptic transmission by the metabotropic glutamate receptor 7.

Authors:  J Perroy; O El Far; F Bertaso; J P Pin; H Betz; J Bockaert; L Fagni
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

Review 2.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

3.  Selective blockade of P/Q-type calcium channels by the metabotropic glutamate receptor type 7 involves a phospholipase C pathway in neurons.

Authors:  J Perroy; L Prezeau; M De Waard; R Shigemoto; J Bockaert; L Fagni
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

4.  Involvement of metabotropic glutamate receptors in ischemia-induced taurine release in the developing and adult hippocampus.

Authors:  P Saransaari; S S Oja
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

5.  Bidirectional modulation of glutamatergic synaptic transmission by metabotropic glutamate type 7 receptors at Schaffer collateral-CA1 hippocampal synapses.

Authors:  Ricardo Martín; José Javier Ferrero; Andrea Collado-Alsina; Carolina Aguado; Rafael Luján; Magdalena Torres; José Sánchez-Prieto
Journal:  J Physiol       Date:  2018-01-25       Impact factor: 5.182

6.  Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7.

Authors:  Colleen M Niswender; Kari A Johnson; Nicole R Miller; Jennifer E Ayala; Qingwei Luo; Richard Williams; Samir Saleh; Darren Orton; C David Weaver; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2009-12-21       Impact factor: 4.436

7.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

Authors:  F Jamen; K Persson; G Bertrand; N Rodriguez-Henche; R Puech; J Bockaert; B Ahrén; P Brabet
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

8.  Biallelic GRM7 variants cause epilepsy, microcephaly, and cerebral atrophy.

Authors:  Dana Marafi; Tadahiro Mitani; Sedat Isikay; Jozef Hertecant; Mohammed Almannai; Kandamurugu Manickam; Rami Abou Jamra; Ayman W El-Hattab; Jaishen Rajah; Jawid M Fatih; Haowei Du; Ender Karaca; Yavuz Bayram; Jaya Punetha; Jill A Rosenfeld; Shalini N Jhangiani; Eric Boerwinkle; Zeynep C Akdemir; Serkan Erdin; Jill V Hunter; Richard A Gibbs; Davut Pehlivan; Jennifer E Posey; James R Lupski
Journal:  Ann Clin Transl Neurol       Date:  2020-04-14       Impact factor: 4.511

Review 9.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

10.  Increases in intracellular calcium triggered by channelrhodopsin-2 potentiate the response of metabotropic glutamate receptor mGluR7.

Authors:  John H Caldwell; Greta Ann Herin; Georg Nagel; Ernst Bamberg; Astrid Scheschonka; Heinrich Betz
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.